A study to find out how safe is it to give people a new medicine called “GDC-8264” – including the effect of food on GDC-8264, and the effect of combining GDC-8264 with other medicines

Healthy volunteers for single ascending dose (SAD; n=38), multiple ascending dose (MAD; n=15), and drug-drug interaction (DDI; n=15) cohorts were enrolled at one study site in the Netherlands to evaluate the safety and tolerability of GDC-8264, with potential activity in patients with inflammatory bowel disease (IBD). All 68 healthy volunteers completed the study and comprised the safety-evaluable population. Results showed single and multiple doses of GDC-8264 taken by mouth were safe and well-tolerated. GDC-8264 can be taken with or without food. One type of measurement indicated DDI, while other measurements did not. There were no deaths or serious adverse events. No single study can tell us everything about the risks and benefits of a medicine. It takes lots of people in many studies to find out everything we need to know. The results from this study may be different from other studies with the same medicine.